The National Institute of Allergy and Infectious Diseases has awarded Sorrento Therapeutics two small business research grants worth up to $2.6 million to support development of two antibacterial immunotherapies. Sorrento will use the grants to further develop a human bispecific antibody designed to prevent and treat Staphylococcus aureus infections and to develop an antibody-mediated targeted antibiotic delivery vehicle or a monoclonal antibody immunotherapy for Pseudomonas aeruginosa infections.

Related Summaries